Metformin use before COVID-19 vaccination and the risks of COVID-19 incidence, medical utilization, and all-cause mortality in patients with type 2 diabetes mellitus.

ABSTRACT:

Aims

We designed this study to determine whether metformin use before COVID-19 vaccination influences the risk of COVID-19 infection, medical utilization, and mortality.

Methods

We used the US collaborative network of TriNetX to identify 123,709 patients with type 2 diabetes mellitus fully vaccinated against COVID-19 between January 1, 2020, and November 22, 2022. The study selected 20,894 pairs of metformin users and nonusers by propensity score matching. The Kaplan-Meier method and Cox proportional hazards models were used to compare the risks of COVID-19 infection, medical utilization, and mortality between the study and control groups.

Results

No significant difference was noted between metformin users and nonusers in the risk of COVID-19 incidence (aHR = 1.02, 95

SUBMITTER: Yen FS 

PROVIDER: S-EPMC10163786 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature